Results 81 to 90 of about 2,751,693 (208)

New Hydrazone Derivatives Featuring Isatin and Piperazine Moieties: Synthesis, Cytotoxicity Evaluation, and Molecular Modeling Studies

open access: yesJournal of Applied Toxicology, Volume 46, Issue 12, Page 4583-4598, December 2026.
ABSTRACT In this study, ten novel compounds (IPH1–IPH10) were designed by integrating three pharmacophores (isatin, piperazine, and hydrazone) commonly found in the molecular structures of anticancer agents. The target molecules were obtained by the reaction of in‐house prepared 4‐(4‐(pyridin/pyrimidin‐2‐yl)piperazin‐1‐yl)benzohydrazide with various ...
Semiha Köprü   +3 more
wiley   +1 more source

New agent overcomes resistance to imatinib

open access: yes, 2005
A drug that can overcome resistance to imatinib in patients with chronic myelogenous leukaemia (CML) has been developed by US researchers (Proc Natl Acad Sci USA, published online Jan 27, 2005, DOI: 10.1073/pnas.0408283102). Imatinib selectively inhibits
Ahmed, Khabir, Khabir Ahmad
core   +1 more source

Inhibition of the Nrf2-TrxR Axis Sensitizes the Drug-Resistant Chronic Myelogenous Leukemia Cell Line K562/G01 to Imatinib Treatments [PDF]

open access: yes, 2019
Nuclear factor erythroid 2-related factor 2 (Nrf2) is involved in tumor drug resistance, but its role in imatinib-resistance of chronic myeloid leukemia (CML) remains elusive.
Yanhong, Tan   +11 more
core   +1 more source

The role of the lysine histone methylase KMT2D in chronic myeloid leukemia

open access: yesFrontiers in Pharmacology
Chronic myeloid leukemia (CML) can be effectively treated inhibiting the disease-causing BCR::ABL1 kinase by tyrosine kinase inhibitors (TKIs). Although therapy is initially tremendously successful, resistance may occur in up to 25% of CML patients ...
Lina Schlemminger   +4 more
doaj   +1 more source

Eosinophilia and Hypereosinophilia: A Practical Approach to Navigating a Broad Differential Diagnosis

open access: yesEuropean Journal of Haematology, Volume 117, Issue 6, Page 1485-1499, December 2026.
ABSTRACT Eosinophilia, defined as an absolute eosinophil count (AEC) of ≥ 0.5 × 109/L, is a frequently encountered finding with a vast spectrum of potential underlying etiologies. Hypereosinophilia (HE) is defined as AEC > 1.5 × 109/L and may become life‐threatening when eosinophil‐induced organ damage occurs, defining the hypereosinophilic syndrome ...
Stijn Wigerinck, Peter Vandenberghe
wiley   +1 more source

Re‐Purposing Sapropterin (Kuvan) for ACTA2‐Related Multisystemic Smooth Muscle Dysfunction Syndrome: A Translational Mechanistic and First‐In‐Human Therapeutic Report

open access: yesAnnals of Clinical and Translational Neurology, Volume 13, Issue 11, Page 2375-2381, November 2026.
ABSTRACT Multisystemic smooth muscle dysfunction syndrome (MSMDS) is an ultra‐rare, ACTA2‐related disorder characterized by severe cerebrovascular disease, aortic aneurysms, and smooth muscle dysfunction. Using molecular dynamics simulations and in silico drug screening, we identified that sapropterin dihydrochloride (Kuvan) is a candidate capable of ...
Moran Hausman‐Kedem   +9 more
wiley   +1 more source

Outcomes for post‐transplant relapsed acute lymphoblastic leukaemia in the era of novel therapies: A retrospective multicentre UK study

open access: yes
British Journal of Haematology, EarlyView.
Alexandros Rampotas   +16 more
wiley   +1 more source

Repurposing FDA‐Approved Drugs to Inhibit Fungal PPTases for Broad‐Spectrum Synergy

open access: yesAdvanced Science, Volume 13, Issue 63, 12 November 2026.
Fungal secondary metabolites serve as crucial virulence effectors; however, the potential of their biosynthetic pathways as antifungal targets remains inadequately comprehended. Repurposed FDA‐approved drugs inhibit fungal PPTase (essential for secondary metabolism) in vivo.
Zili Song   +7 more
wiley   +1 more source

Impact of non-coding RNAs on resistance to imatinib in chronic myelogenous leukemia

open access: yesLeukemia Research Reports
Imatinib is approved as the first-line treatment for newly diagnosed chronic myelogenous leukemia (CML). In spite of profound response in the majority of patients, resistance occurs in a subgroup of CML cases.
Fatemeh Ensafi Talemi   +1 more
doaj   +1 more source

RUNX1T1 is overexpressed in imatinib mesylate-resistant cells

open access: yesMolecular Medicine Reports, 2009
The Philadelphia (Ph) chromosome, which occurs as a result of a translocation between chromosomes 9 and 22, generates a BCR-ABL fusion oncogene in leukaemia cells. The BCR-ABL fusion protein has constitutive tyrosine kinase activity. The development of imatinib mesylate (STI571, Gleevec®), a potent and selective BCR-ABL tyrosine kinase inhibitor ...
Renata, Binato   +5 more
openaire   +3 more sources

Home - About - Disclaimer - Privacy